Company Overview

Medtronic plc is an American-Irish medical device company with legal and executive headquarters in Ireland and operational headquarters in Minneapolis, Minnesota. Founded in 1949, it is one of the world's largest medical technology companies and currently the largest medical device company globally by revenue. Medtronic boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Their mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. While it primarily operates in the United States, its extensive global reach and workforce underscore its significant international presence.

Business Segments

Medtronic operates through four distinct and critical business segments:

Cardiovascular Portfolio

This segment is dedicated to the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. It offers a comprehensive range of products, including implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices. The portfolio also features cardiac ablation products, insertable cardiac monitor systems, TYRX products, and advanced remote monitoring and patient-centered software solutions.

Neuroscience Portfolio

The Neuroscience Portfolio encompasses a wide array of technologies focused on the brain and spine. It includes cranial and spinal technologies, specialty therapies, and neuromodulation divisions, addressing a broad spectrum of neurological conditions.

Medical Surgical Portfolio

This segment provides essential tools and technologies for surgical procedures and patient care. It offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, an AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and products for patient monitoring and airway management.

Diabetes Operating Unit

The Diabetes Operating Unit is focused on managing diabetes through innovative technology. It provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and the InPen, a smart insulin pen, to help patients manage their condition effectively.

Recent Financial Performance

Q1 FY2026 Results (ended July 25, 2025)

Medtronic reported robust performance for the first quarter of fiscal year 2026. Revenue stood at $8.6 billion, with adjusted revenue at $8.5 billion, marking an increase of 8.4% as reported and 4.8% organically. GAAP diluted Earnings Per Share (EPS) was $0.81, a 1% increase, while non-GAAP diluted EPS reached $1.26, up 2%. Non-GAAP net income for the quarter was $1.626 billion, also a 2% increase.

FY2025 Performance

For the full fiscal year 2025, Medtronic achieved total revenue of $33.54 billion, representing a 3.62% increase compared to the previous year's $32.36 billion. Earnings for the year amounted to $4.66 billion, showing a significant increase of 26.82%.

Market Position and Innovation

Medtronic has a distinguished history of pioneering world-first technologies. Since its inception, the company has introduced innovations such as wearable and implantable pacemakers, the implantable cardioverter defibrillator, and remote monitoring systems. Its technologies and therapies address 70 health conditions and span cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and much more. Medtronic delivers innovative technologies that transform the lives of two people every second, every hour, every day.

Recent Growth Drivers

The Cardiovascular Portfolio, particularly Cardiac Ablation Solutions, has seen substantial growth, with revenue increasing nearly 50%, driven significantly by strong performance in pulsed field ablation (PFA) products, including a 72% surge in the US market. The company continues to experience robust performance across its diverse segments, supported by multiple diversified growth drivers.

Dividend History and Shareholder Returns

Medtronic boasts an impressive and long-standing history of dividend growth, solidifying its status as a constituent of the S&P 500 Dividend Aristocrats index. The company has demonstrated its commitment to shareholders with 47 consecutive years of dividend increases. Over the past five years, Medtronic's dividend per share has grown by 30%, and over the last decade, it has increased by 130%. Looking back over 47 years, the dividend has grown at a compounded annual growth rate of 16%.

As of May 2024, the quarterly dividend was raised to $0.70 per ordinary share, resulting in an annual payout of $2.80 per ordinary share. The dividend yield was approximately 3.33% in 2024, with a payout ratio reaching 77.47%.

Forward Guidance

The company has reaffirmed its revenue growth expectations for FY26 and has raised its EPS guidance. Medtronic continues to anticipate an organic revenue growth of approximately 5% for FY26. On a reported basis, the projected revenue growth for FY26 is expected to be in the range of 6.5% to 6.8%. Medtronic now forecasts an underlying FY26 diluted non-GAAP EPS growth of approximately 4.5%, an upward revision from the prior guidance of approximately 4%.

Strategic Focus

Medtronic is enhancing its confidence by advancing key revenue growth drivers and implementing operational efficiencies across manufacturing, supply chain, and operating expenses to bolster earnings growth. Concurrently, the company is increasing its investments in Research & Development, sales, and marketing, all with a deliberate focus on creating sustained, long-term shareholder value.

The company remains exceptionally well-positioned as a global leader in healthcare technology, supported by a diversified portfolio of medical devices and therapies that address critical healthcare needs worldwide. With consistent dividend growth spanning nearly five decades and ongoing innovation across multiple therapeutic areas, Medtronic continues to demonstrate its unwavering commitment to delivering substantial value to both patients and shareholders.